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IMPORTANCE Anakinra, an interleukin 1β recombinant receptor antagonist, may have
potential to treat colchicine-resistant and corticosteroid-dependent recurrent pericarditis.
OBJECTIVE To determine the efficacy of anakinra for colchicine-resistant and
corticosteroid-dependent recurrent pericarditis.
DESIGN, SETTING, AND PARTICIPANTS The Anakinra—Treatment of Recurrent Idiopathic
Pericarditis (AIRTRIP) double-blind, placebo-controlled, randomized withdrawal trial (open
label with anakinra followed by a double-blind withdrawal step with anakinra or placebo until
recurrent pericarditis occurred) conducted among 21 consecutive patients enrolled at 3 Italian
referral centers between June and November 2014 (end of follow-up, October 2015).
Included patients had recurrent pericarditis (with3 previous recurrences), elevation of
C-reactive protein, colchicine resistance, and corticosteroid dependence.
INTERVENTIONS Anakinra was administered at 2 mg/kg per day, up to 100mg, for 2 months,
then patients who responded with resolution of pericarditis were randomized to continue
anakinra (n = 11) or switch to placebo (n = 10) for 6months or until a pericarditis recurrence.
MAIN OUTCOMES ANDMEASURES The primary outcomeswere recurrent pericarditis and time
to recurrence after randomization.
RESULTS Eleven patients (7 female) randomized to anakinra had amean age of 46.5 (SD,
16.3) years; 10 patients (7 female) randomized to placebo had amean age of 44 (SD, 12.5)
years. All patients were followed up for 12 months. Median follow-up was 14 (range, 12-17)
months. Recurrent pericarditis occurred in 9 of 10 patients (90%; incidence rate, 2.06% of
patients per year) assigned to placebo and 2 of 11 patients (18.2%; incidence rate, 0.11% of
patients per year) assigned to anakinra, for an incidence rate difference of −1.95% (95% CI,
−3.3% to −0.6%). Median flare-free survival (time to flare) was 72 (interquartile range,
64-150) days after randomization in the placebo group and was not reached in the anakinra
group (P <.001). During anakinra treatment, 20 of 21 patients (95.2%) experienced transient
local skin reactions: 1 (4.8%) herpes zoster, 3 (14.3%) transaminase elevation, and 1 (4.8%)
ischemic optic neuropathy. No patient permanently discontinued the active drug. No adverse
events occurred during placebo treatment.
CONCLUSION AND RELEVANCE In this preliminary study of patients with recurrent pericarditis
with colchicine resistance and corticosteroid dependence, the use of anakinra compared with
placebo reduced the risk of recurrence over a median of 14months. Larger studies are
needed to replicate these findings as well as to assess safety and longer-term efficacy.
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R ecurrentpericarditis is adifficult clinicalproblem1,2 thataffects up to 30% of patients after a first episode ofacute pericarditis3 and up to 50% of those with a first
recurrence, if not treatedwith colchicine.4,5 Theoptimal regi-
men for avoiding recurrences has not been clearly estab-
lished.Treatmentmodes in recurrentpericarditis includenon-
steroidal anti-inflammatory drugs (NSAIDs), corticosteroids,
colchicine, immunosuppressiveagents,andpericardiectomy.1,2
Quality of life may be severely affected in frequently relaps-
ing cases, and patients with frequent recurrences can de-
velop corticosteroid dependence.
Anakinra is an interleukin (IL) 1β recombinant receptor an-
tagonist that has been proposed as a potential treatment for
recurrent pericarditis. Anakinra was used first in pediatric
patients,6 then evaluated in adults.7 Anakinra administered
daily subcutaneously for several months showed a rapid re-
sponse with corticosteroid withdrawal in both children and
adults.7,8 Current evidence for anakinra is based entirely on
case reports and retrospective series9; to our knowledge, no
randomized clinical trials have been conducted.
The aim of this randomized clinical trial was to evaluate
the efficacy and tolerability of anakinra in adults and chil-
dren with recurrent idiopathic pericarditis that was cortico-
steroid dependent and colchicine resistant.
Methods
Study Design
The Anakinra—Treatment of Recurrent Idiopathic Pericardi-
tis (AIRTRIP) study was an investigator-initiated, 8-month,
multicenter, randomized, double-blind, placebo-controlled,
medicationwithdrawal study to evaluate the efficacy and tol-
erability of anakinra in adults and childrenwith idiopathic re-
currentpericarditis.Thestudywasapprovedbytheethicscom-
mittees at each participating center. All adult patients or the
parents of pediatric patients provided written informed con-
sent. The trial was registered at EudraCT onMay 9, 2013, and
was subsequently also registered at ClinicalTrials.gov. It con-
sisted of 2 parts: (1) an open-label treatment period in which
anakinra was administered daily for 60 days, followed by
(2) a double-blind withdrawal period in which patients who
had a sustained complete response in part 1 were random-
ized to receive anakinra or placebo daily for up to 6 months.
The end of the studywas the end of part 2 (8months after en-
rollment) or the time of relapse,whichever occurred first. Pa-
tientswhohadanother pericarditis recurrence couldhave the
option tobe retreatedwithanakinra.All patientswere then fol-
lowed up for another 4 months to assess safety (Figure 1).
The trial protocol and statistical analysis plan are avail-
able in Supplement 1.
Patients
Between June and November 2014, all consecutive cortico-
steroid-dependent patients with recurrent pericarditis (with
≥3 previous recurrences) were enrolled at the time of a recur-
rence of pericarditis until a population of at least 21 patients
was achieved.
Inclusion Criteria
All patients eligible for inclusion in this study had recurrent
idiopathic pericarditis, defined as a first episodeof acuteperi-
carditis followed by recurrences (with ≥3 previous recur-
rences), andwereolder than2years andyounger than70years
at the screening visit. The first episode of pericarditis was di-
agnosedwhenat least2of thefollowingcriteriawerepresent3-5:
pericarditic-typical chest pain (sharp and pleuritic, improved
by sitting up and leaning forward), pericardial friction rubs,
widespread ST-segment elevation or PR depressions not pre-
viously reported, and new or worsening pericardial effusion.
Recurrencewas diagnosedwhen chest pain reoccurred along
with 1 or more of the following signs: fever, pericardial fric-
tion rub, electrocardiographic changes, or echocardiographic
evidenceofneworworseningpericardial effusion.3-5Tobeen-
rolled in this study, increased concentrationofC-reactivepro-
tein (CRP) was mandatory both in the first attack and in the
following recurrences,with a value greater than 1mg/dL (nor-
mal range considered0-0.5mg/dL), aswell as treatmentwith
corticosteroids. All patients had corticosteroid dependence
(drug tapering orwithdrawal invariably followedby anew re-
lapse). Pericarditis that was secondary to specific etiologies
were excluded, including tuberculous, neoplastic, or puru-
lentetiologies,postcardiac injurysyndromes,andsystemicdis-
eases including rheumatic autoimmune diseases.
Exclusion Criteria
Patients were not eligible for enrollment if they were preg-
nant or lactating; had ahistory of immunodepression, includ-
ing apositivehuman immunodeficiency virus test result; had
apositiveQuantiFERON(QFT-TBG In-Tube) test result orposi-
tive purified protein derivative test result (≥5-mm indura-
tion) after the first attack of pericarditis (patients with a posi-
tivepurifiedproteinderivative test result [≥5-mminduration]
at screening could be enrolled only if they had either a nega-
tive chest x-ray result or a negativeQuantiFERON test result);
had any live vaccinationswithin 3months prior to the start of
the trial; had a history of malignancy of any organ system,
treated or untreated, within the past 5 years; had a history of
significant othermedical conditions that in the investigator’s
opinionwouldexcludeapatient fromparticipating in this trial;
Key Points
Question Is anakinra, an interleukin 1β recombinant receptor
antagonist, effective in the treatment of recurrent pericarditis
among patients with colchicine resistance and corticosteroid
dependence?
Findings In this double-blind, placebo-controlled, randomized
withdrawal trial of 21 patients, recurrent pericarditis occurred in 9
of 10 patients assigned to placebo and 2 of 11 patients assigned to
anakinra, a significant difference.
Meaning In patients with recurrent pericarditis with colchicine
resistance and corticosteroid dependence, anakinra compared
with placebo reduced the risk of recurrence over a median of 14
months. Larger-scale trials are needed for confirmation of these
findings.
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or had a history of recurrent and/or evidence of active bacte-
rial, fungal, or viral infection(s).
Study Drug Administration and Randomization
Patients fulfillingstudyentrycriteria receivedopen-label treat-
ment with anakinra (adults: 100mg/d; children: 2 mg/kg per
dayup to 100mg) subcutaneously. A clinical, laboratory, elec-
trocardiographic, andechocardiographic assessmentwasper-
formed at study day 1 (baseline), day 4 (after 72 h of treat-
ment), and day 8. On day 4, patients were divided into 2
categories. Thosewith a reduction of 30%ormore frombase-
line pericardial pain on a 21-circle visual analog scale (VAS)
(aVAS from0-10 cm inwhich the values are increasedby0.25
at every circle),10 a 30%or greater decrease inCRP concentra-
tion, and no increase in pericardial effusion on echocardio-
gram continued the study. Patients who eventually did not
meet these criteria were considered to have “early treatment
failures,” and the protocol allowed rescue therapy as per phy-
sician decision andwithdrawal from the study and follow-up
for safety (Figure 1 and Supplement 1). Responder status was
again assessed at day 8. At day 8, responders withdrew from
NSAIDsandcorticosteroids (see sectiononco-medicationsbe-
low). Treatment with anakinra was continued until day 60,
when all 21 patients were randomized in a double-blind fash-
ion to continue anakinra (n=11) or to switch to placebo (n=10)
for another 6months. Placebowasdeliveredby a syringewith
identical appearance to the study drug.
Participantswere randomly assigned in a 1:1 ratio to treat-
ment groups by a computer-based automated sequence, and
patients and physicians were blinded.
Co-medications
Patients could enter the studywhile takingwhatevermedica-
tions theywereusing to treat their pericarditis except forother
IL-1 blockers. All enrolled patients were being treated with
long-term corticosteroid therapy,with the dose of corticoste-
roidsnot increased in the3daysprecedingenrollment.Allwere
also being treated with colchicine at enrollment or previ-
ously (colchicine was previously withdrawn in 1 patient for
lack of efficacy and in 2 for poor tolerability [Table 1]).
Co-medications had to remain unchanged in responders un-
til day 8. In responders at day 8, medications were tapered:
NSAIDs were tapered andwithdrawnwithin 15 days; cortico-
steroid therapywasprogressively tapered and stoppedwithin
6 weeks from response. Prednisone (or equivalent) tapering
was 5 mg every week in adults and 0.2 mg/kg every week in
children. Colchicine discontinuation was optional.
Follow-up andOutcomes
Patients underwent clinical and laboratory evaluations at
months 1, 2, 4, 6, and 8 or at time of relapse, whichever oc-
curred first; outcomes assessmentwas blinded to study treat-
ment assignment. If a patient assigned toplacebohad a recur-
rence of pericarditis, open-label treatmentwith anakinrawas
restarted. In case of relapse, as defined below, during the first
2months of open-label therapy the patientwas considered to
have treatment failure. For ethical reasons, if a relapse oc-
curred during the withdrawal phase, the patient was un-
blinded,andpatientswhoreceivedplacebowereretreatedwith
anakinra,whilepatientswhohadbeenreceivinganakinrawere
treated as per physician decision and considered to have late
treatment failure.
The primary end points were pericarditis recurrence rate
at 8 months and time to recurrent pericarditis after random-
ization. Secondary end points were responder status, time to
response in the open-label phase (time frame, 60 days), and
percentage of patients with corticosteroid withdrawal at 6
weeks. To assess responder status in the open-label phase, at
days 8 and 60 the following 3 criteria all had to be met: no or
mild pericardial pain (a score ≤2.5 on a 21-circle VAS), normal
CRPconcentration (C≤0.5mg/dL),andabsentormild (≤10-mm)
echocardiographiceffusion.Thestudyendedwith thecomple-
tion of the last follow-up at 8 months.
Statistical Analysis
This trial followedthe recommendationof theCONSORTstate-
ment, with results reported by the intention to-treat prin-
ciple in the double-blind withdrawal phase. Sample size was
estimated to be 20patients.Weestimated that 10patients per
groupwould be sufficient to detect a difference in recurrence
rate from 80% in the placebo group to 10% in anakinra pa-
tients with a power of 90% at a confidence level of 95%. The
study hypothesis was that anakinra could reduce the ex-
pected recurrence rate from80%to10%.6-9,11-15Event-free sur-
vival was estimated by the Kaplan-Meier method. A 2-sided
Figure 1. Participant Flow in the AIRTRIP Randomized Clinical Trial
25 Patients screened for eligibility 
21 Patients enrolled at the time of a recurrence
of acute pericarditis (open-label phase)
21 Patients started anakinra on day 1
21 Patients assessed for early treatment
failure on day 4; no failures recordeda
21 Patients assessed for responder
status on day 8
21 Had complete response and
discontinued NSAID and
corticosteroid treatment
within 6 weeks
4 Patients excluded
1 Declined to participate
3 Had no recurrences of acute
pericarditis during enrollment
period 
21 Patients randomized (day 60; start
of double-blind withdrawal phase)
11 Patients included in the analysis
11 Patients randomized to
continue anakinra
11 Received anakinra as
randomized
10 Patients randomized to
switch to placebo
10 Received placebo as
randomized
10 Patients included in the analysis
NSAID indicates nonsteroidal anti-inflammatory drug.
a To allow early rescue therapy in case of failure of anakinra.
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log-rank test was used to compare the time to flare between
randomization and the end of month 8 in the 2 treatment
groups. The Fisher exact test was used to evaluate rate of re-
currence in the withdrawal phase. Incidence rates of recur-
rence in the anakinra andplacebogroupswere estimatedwith
their 95% confidence intervals, as well as the incidence rate
difference and incidence rate ratio between the 2 groups.
All tests were 2-tailed, and a P<.05 was considered statisti-
cally significant. Analyses were performed using STATA soft-
ware, release 13.
Results
Patients
Atotal of 25patientswere screened for entry in the study from
3centers in Italy, and21were enrolled. Studyenrollment, ran-
domization, and retention are shown in Figure 1. Demo-
graphicandbaselinecharacteristicsweresimilar in the2groups
(Table 1).
Mean age was 45.4 years (range, 15-69 years; 14 were fe-
male). Onepatientwas in thepediatric age range (15 years old)
and the remaining 20 patients were adults (aged >18 years).
Meannumber of recurrences before the studywas 6.8 (range,
3-16), with a clinical history of recurrent pericarditis lasting
27.8months on average (range, 4-100months).Median dura-
tion of follow-up was 14 (range, 12-17) months.
Open-Label Phase
At the time of study enrollment, all 21 patients were ex-
periencing a recurrence of pericarditis with a mean VAS
pain score of 7.7 (range, 3.5-10); the mean CRP level was
4.2 (range, 1-16.1) mg/dL. Eighteen patients had evidence of
pericardial effusion, which was mild in all cases (<10 mm)
(eTable in Supplement 2).
Allpatientshadacomplete responsetoopen-labelanakinra
treatment at day 8 (according to the protocol definition) that
was maintained until randomization (day 60).
C-reactive protein was normalized in all patients at day 8
and remained at normal levels at day 60. Pain VAS scores
quickly decreased; and the mean score was 0.4 at day 60
(range, 0-2). Also, patients’ or parents’ global assessment of
overall well-being on a 21-circle VAS greatly improved over
time; mean scores were 5.8 at day 0 and 1.6 at day 60 (10
indicates the worst quality).
All patients successfully discontinued corticosteroids
within 6 weeks and proceeded to the double-blind with-
drawalphase.At randomization (day60),CRP levelswerenor-
mal in all 21 patients, mean pain VAS scorewas 0.4, and none
of the 21 patients were taking corticosteroids or NSAIDs.
Double-BlindWithdrawal Phase
During the double-blind treatment phase, recurrence of
pericarditis occurred in 9 (90%) of the 10 patients random-
ized to placebo (incidence rate, 2.06% of patients per year;
95% CI, 1.07%-3.97%) and in 2 (18.2%) of the 11 patients ran-
domized to anakinra (33 and 120 days after randomization)
(incidence rate, 0.11% of patients per year; 95% CI, 0.03%-
0.45%). The incidence rate difference was −1.95% (95% CI,
−3.3% to −0.6%) and the incidence rate ratio was 0.055
(95% CI, 0.006-0.264; Table 2). Median flare-free survival
(time to flare) was 72 (interquartile range, 64-150) days after
randomization in the placebo group; it could not be calcu-
lated in the anakinra group (P<.001). Half the patients
Table 1. Participant Characteristics at Enrollment and Randomization
Characteristics
At Enrollment At Randomization
All Patients
(n=21)
Anakinra
(n=11)
Placebo
(n=10)
Anakinra
(n=11)
Placebo
(n=10)
Sex, No. (%)
Male 7 (33.3) 4 (36.4) 3 (30.0)
Female 14 (66.6) 7 (63.6) 7 (70.0)
Age, y
Mean (SD) 45.4 (14.3) 46.5 (16.3) 44 (12.5)
Range 15-69 15-69 26-66
Time with pericarditis,
mean (SD), mo
27.8 (25.3) 29.2 (28.8) 26.0 (22.2)
Pain VAS score, mean (SD)a 7.7 (1.7) 7.1 (1.8) 8.3 (1.3) 0.3 (0.5) 0.5 (1.1)
CRP level, mean (SD), mg/dL 4.2 (3.9) 3.7 (2.2) 4.8 (5.3) 0.2 (0.2) 0.3 (0.2)
Pericardial effusion, No. (%) 18 (85.7) 9 (81.8) 9 (90.0) 0 0
Previous recurrences
of pericarditis, No.
Mean (SD) 6.8 (3.6) 6.9 (2.9) 6.7 (4.3)
Range 3-16 3-12 3-16
Therapy, No. (%)
Corticosteroids 21 (100) 11 (100) 10 (100) 0 0
NSAIDs 15 (71.4) 8 (72.7) 7 (70.0) 0 0
Colchicine 18 (85.7) 10 (90.9) 8 (80.0) 6 (54.5) 6 (60.0)
Abbreviations: CRP, C-reactive
protein; NSAIDs, nonsteroidal
anti-inflammatory drugs.
a Higher pain visual analog scale
(VAS) scores indicate higher pain on
a 0- to 10-point scale.
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assigned to placebo were free of flare 72 days after random-
ization, while more than half of patients assigned to
anakinra were still free of recurrence at the end of the study
(P<.001; Figure 2). In patients with recurrences, the mean
time to flare was 28.4 (range, 2-90) days vs 76.5 (range,
33-120) days in the placebo and anakinra groups, respec-
tively, resulting in an absolute mean difference of −48.1
(95% CI, −118.1 to 21.9) days.
Nine patients (4 randomized to placebo and 5 random-
ized to anakinra) discontinued colchicine and 12 patients
(6 randomized to placebo and 6 randomized to anakinra)
maintained colchicine therapy (according to physician and
patient decisions). During the double-blind treatment, con-
current treatment with colchicine did not significantly
affect recurrence rate (7/12 [58.3%] with colchicine and 4/9
[44.4%] without colchicine), and time to flare (median flare-
free survival, 90 days with colchicine; could not be calcu-
lated in the noncolchicine group; log-rank P = .77), but the
study did not have the power to compare monotherapy with
anakinra vs combined therapy with anakinra plus colchi-
cine. In patients with recurrences, the mean time to flare
was 52.7 (range, 2-120) days in the colchicine group vs 10
(range, 4-16) days in the noncolchicine group, respectively,
resulting in an absolute mean difference of −42.7 (95% CI,
−97.1 to 11.7) days.
Adverse Events
The most common adverse effect in anakinra-treated pa-
tientswas a local reaction at the injection site, observed in 20
of 21 patients (95%) during the initial open-label phase; gen-
erally, reactions disappeared over 1month; 3 patients tempo-
rarily discontinued anakinra in the open-label phase but re-
sumed it after topical treatment and systemic antihistamines,
and no patient discontinued the study for this adverse effect
(Table 3). Herpes zoster occurred in 1 patient treated with
anakinra during the open-label phase of the study, leading to
temporary discontinuation of anakinra.
A69-year-oldhypertensive andhypercholesterolemicpa-
tient in theanakinragroupdeveloped ischemicopticneuropa-
thy at day210 (in thedouble-blindwithdrawal phase) that did
not appear to be related to the experimental treatment.
Three patients (14.3%) showed an elevation of transami-
nases (<2 times normal values) in the open-label phase, re-
versible after temporary discontinuation or dose reduction of
anakinra.
No adverse effects were recorded during treatment with
placebo.
Discussion
To our knowledge, this is the first randomized clinical trial to
assess the efficacy of anakinra for refractory idiopathic recur-
rentpericarditiswith corticosteroiddependenceandafter fail-
ure of colchicine therapy. In this study, we observed that
anakinra allowed corticosteroid withdrawal in all patients.
Moreover, flares of pericarditis were markedly reduced, oc-
curring in 9 of 10patients (90%) randomized to placebo and2
of 11patients (18%) randomized toanakinraduring thedouble-
blind treatment.
Refractory recurrent pericarditis is a major clinical man-
agement issuebecause it is corticosteroiddependent anddoes
not respond to colchicine; thus, patients are unable to with-
draw corticosteroids without a relapse. Corticosteroids im-
pair growth in children, and Picco et al6 described the first 3
patients, all children, successfully treated with anakinra; at
present, 10 reports describing 46 patients (adults and chil-
dren) have been published.6-8,11-17 The 2015 guidelines of the
European Society of Cardiology18 stated that anakinra, aza-
thioprine, and high-dose intravenous immunoglobulinsmay
Table 2. Primary End Points: Pericarditis Recurrence Rate and Time to Flare After Randomization
End Points
Placebo
(n=10)
Anakinra
(n=11) Difference (95% CI) P Value
Risk of recurrence, No. (%) 9 (90) 2 (18) −0.718 (−1.01 to −0.42) .001a
Incidence rate, % patients/y
(95% CI)
2.06 (1.07-3.97) 0.11 (0.03-0.45) −1.95 (−3.3 to −0.6)
Incidence rate ratio (95% CI) 1 [Reference] 0.055 (0.006-0.264) <.001b
Time to flare
Flare-free survival, median
(interquartile range), d
72 (64-150) Not calculable <.001c
Days to flare, mean (range)d 28.4 (2-90) 76.5 (33-120) −48.1 (−118.1 to 21.9) <.001e
a By Fisher exact test.
b By χ2 test.
c By log-rank test.
d Calculated for patients with
recurrences.
e ByWilcoxon rank-sum test.
Figure 2. Kaplan-Meier Analysis of PatientsWith Recurrent Pericarditis
Free of Relapse in the Double-BlindWithdrawal Phase, FromDay 0
to Day 180 After Randomization (Intention-to-Treat Analysis)
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be considered in corticosteroid-dependent recurrent pericar-
ditis that is resistant or intolerant to colchicine, but the level
of evidencewas low (C, based on case series and expert opin-
ion).This study is the first randomized,placebo-controlled trial
of anakinra for idiopathic recurrent pericarditis showing that
anakinra is apotential option for this subset of patients. These
findingsalsoprovideevidence that IL-1playsan important role
in the pathogenesis of idiopathic recurrent pericarditis.6,19
Anakinra use is associated with an increased risk of ad-
verseeffects,especially relatedto injectionsite reactions.These
generally occurred early after drug delivery, were relatively
transient (generally a fewweeks), and canbe treatedwithoral
antihistamines and topical corticosteroids.20Warming the sy-
ringe to room temperature before use is advisable, alongwith
application of a cold pack to the injection site approximately
2 to 3minutes before and immediately after the injection. Pa-
tients should be informed in advance about the potential for
suchreactions topreventunjustifieddrugdiscontinuation.Ad-
ditional potential adverse effects include transaminase eleva-
tion thatwas observed in 3 (14.3%) of 21 patients andwas lim-
itedand transient.Themost importantpotential adverseeffect
is an increased risk of infections; in our study, 1 patient (4.7%)
developed herpes zoster and required temporary discontinu-
ation of the study drug.
The first use of anakinra dates to 199621; serious infec-
tions are rare, and in a review of 5 clinical trials, they ap-
peared in 1.7% of patients in the active treatment group com-
paredwith0.7% in theplacebogroup.22Neutropeniahasbeen
reported in approximately 5% of cases but without evidence
of association with clinical events.22-24
Anakinra has both advantages and disadvantages to con-
sider in treatingpatients similar to those in this study.Themain
advantages of the drug are a rapid onset of effect and the ca-
pability to allowaquickwithdrawalof corticosteroids.Thepo-
tentialdisadvantages includea longdurationof therapyaswell
as high costs. Strict selectionof patients is important: onlypa-
tientswitha clear inflammatorypatternare candidates for this
therapy.Suchpatientsusuallyhaveahistoryofhighfever, strik-
ingly elevated levels of CRP, and pleural effusion, particu-
larly in the pediatric age range; these clinical signs are likely
associated with a pivotal pathogenic role of IL-1. Conversely,
patientswithmildordoubtful symptomsand/ornormalornear
normal levels of CRP are not good candidates for anti–IL-1
therapy.25
Themain limitation of this study is its small sample size.
However, given the large treatment effect, the current study
had the statistical power to verify the initial study hypoth-
esis. The sample size was inadequate to assess true fre-
quencyofadverseevents.Weacknowledge theextremelywide
confidence intervals and, hence, imprecision around the pri-
mary outcome. An additional limitation is the median fol-
low-up time of 14months,whichmayhave limited the obser-
vations of additional recurrences during follow-up; however,
themainaimof the studywas toassess theefficacyof thedrug
to control the disease and allow corticosteroid withdrawal.
Larger and longer-term studies will be important in the fu-
ture to confirm the findings of the present study. In addition,
the study population was limited to patients with idiopathic
recurrent pericarditis; thus, additional research is needed to
assess the efficacy of anakinra in specific settings such as re-
current pericarditis related to autoimmune diseases. More-
over, future studies are needed to determine whether IL an-
tagonists shouldbe considered the standard therapy for a first
recurrence, instead of corticosteroids.
Conclusions
In this preliminary study of patients with recurrent pericar-
ditis with colchicine resistance and corticosteroid depen-
dence, theuseof anakinra comparedwithplacebo reduced the
risk of recurrence over amedian of 14months. Larger studies
areneeded to replicate these findingsaswell as toassess safety
and longer-term efficacy.
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